<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493596</url>
  </required_header>
  <id_info>
    <org_study_id>CPP-115-0001</org_study_id>
    <nct_id>NCT01493596</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability and Pharmacokinetic Study of CPP-115</brief_title>
  <official_title>A Phase 1, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of CPP-115 Solution Administered Orally to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalyst Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalyst Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      • To evaluate the safety and tolerability of ascending single oral doses of CPP-115&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      • To determine the pharmacokinetic profiles of CPP-115 following administration of a&#xD;
      ascending single oral doses&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Single Oral Doses</measure>
    <time_frame>Days 1-3, 8 &amp; 30</time_frame>
    <description>Number of subjects with clinically significant changes in vital signs, ECG abnormalities changes of cardiac rhythm, serious or severe AEs, and/or clinically significant changes in clinical laboratory evaluations.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Cocaine Dependency</condition>
  <arm_group>
    <arm_group_label>CPP-115 Dose 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPP-115 Dose 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPP-115 Dose 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPP-115 Dose 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPP-115 Dose 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPP-115 Dose 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPP-115</intervention_name>
    <description>Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.</description>
    <arm_group_label>CPP-115 Dose 1</arm_group_label>
    <arm_group_label>CPP-115 Dose 2</arm_group_label>
    <arm_group_label>CPP-115 Dose 3</arm_group_label>
    <arm_group_label>CPP-115 Dose 4</arm_group_label>
    <arm_group_label>CPP-115 Dose 5</arm_group_label>
    <arm_group_label>CPP-115 Dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>An equal volume of water mixed with juice will be administered.</description>
    <arm_group_label>CPP-115 Dose 1</arm_group_label>
    <arm_group_label>CPP-115 Dose 2</arm_group_label>
    <arm_group_label>CPP-115 Dose 3</arm_group_label>
    <arm_group_label>CPP-115 Dose 4</arm_group_label>
    <arm_group_label>CPP-115 Dose 5</arm_group_label>
    <arm_group_label>CPP-115 Dose 6</arm_group_label>
    <other_name>CPP-115</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to give written informed consent and comply with study procedures and&#xD;
             requirements.&#xD;
&#xD;
          2. Males, age 18 to 65 years.&#xD;
&#xD;
          3. Body Mass Index between 19 and 32 kg/m2.&#xD;
&#xD;
          4. Normal systolic blood pressure (BP [90-140 mmHg]), diastolic BP (50 90 mmHg) and heart&#xD;
             rate (HR [resting HR 40-90 beats per minute (bpm)]).&#xD;
&#xD;
          5. Willing and able to abstain from drug, alcohol, and tobacco use during study&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical history and/or findings on physical examination indicating the presence of&#xD;
             clinically significant illness.&#xD;
&#xD;
          2. Clinically significant abnormalities of vital signs or clinical laboratory results&#xD;
             (including hematology, chemistry, and urinalysis).&#xD;
&#xD;
          3. Presence or recent history (within 28 days prior to Screening) of active and&#xD;
             clinically significant (as judged by the Investigator) gastrointestinal, renal,&#xD;
             cardiovascular, hepatic, metabolic, allergic, dermatologic, hematologic, pulmonary,&#xD;
             neurological or psychiatric illness or disorder.&#xD;
&#xD;
          4. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs.&#xD;
&#xD;
          5. Clinically significant ECG abnormalities including QTc ≥ 450 msec.&#xD;
&#xD;
          6. Use of any tobacco-containing or nicotine-containing products (including but not&#xD;
             limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine&#xD;
             lozenges, or nicotine gum) within 6 months prior to Screening.&#xD;
&#xD;
          7. Use of any prescription, illegal, or investigational drug within 28 days prior to Day&#xD;
             1.&#xD;
&#xD;
          8. Use of any over-the-counter (OTC) drug, including vitamins, minerals, dietary/herbal&#xD;
             supplements, or grapefruit or grapefruit juice within 14 days prior to Day 1.&#xD;
&#xD;
          9. Use of alcohol, caffeine, or poppy seed-containing foods or beverages within 72 hours&#xD;
             prior to Day 1.&#xD;
&#xD;
         10. History of recent (within 6 months) drug or alcohol abuse, as defined in DSM IV&#xD;
             (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition).&#xD;
&#xD;
         11. Positive urine drug screen, urine cotinine test, or alcohol breath test at Screening&#xD;
             or check-in to the clinical study unit (CSU). Subjects with results believed to be&#xD;
             false positives can be allowed to screen while results are retested at a specialized&#xD;
             laboratory.&#xD;
&#xD;
         12. Positive serology for the surface antigen of Hepatitis B (HBsAg), Hepatitis C (anti&#xD;
             HCV), or human immunodeficiency virus (HIV) antibody screen.&#xD;
&#xD;
         13. Donation of blood or plasma to a blood bank or for a clinical study (except for study&#xD;
             screening) within 28 days prior to Day 1.&#xD;
&#xD;
         14. Receipt of blood products within 2 months prior to Screening.&#xD;
&#xD;
         15. Any condition or other reason that, in the opinion of the Investigator, would render&#xD;
             the subject unsuitable for the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mardik Donikyan, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinilabs, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinilabs, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 28, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <results_first_submitted>February 8, 2021</results_first_submitted>
  <results_first_submitted_qc>March 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2021</results_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase 1 unit. Groups of 8 normal volunteer male subjects were screened &amp; returned to unit evening before they were to receive their specified dose.</recruitment_details>
      <pre_assignment_details>Overnight fast prior to receiving dose</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CPP-115 Dose 1</title>
          <description>Cohort 1 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="P2">
          <title>CPP-115 Dose 2</title>
          <description>Cohort 2a consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="P3">
          <title>CPP-115 Dose 2 (Repeat)</title>
          <description>Cohort 2(b) consisted of 7 subjects with 5 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="P4">
          <title>CPP-115 Dose 3</title>
          <description>Cohort 3 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="P5">
          <title>CPP-115 Dose 4</title>
          <description>Cohort 4 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="P6">
          <title>CPP-115 Dose 5</title>
          <description>Cohort 5 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="P7">
          <title>CPP-115 Dose 6</title>
          <description>Cohort 1 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7">Repeat of dose cohort because of incidences of hyperkalemia observed in cohort 2(a).</participants>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects randomized to drug had plasma and urine levels of drug analyzed to produce pharmacokinetic profiles (e.g. time to maximum concentration (Cmax), half life (t1/2), area under the curve (AUC)</population>
      <group_list>
        <group group_id="B1">
          <title>CPP-115 Dose 1</title>
          <description>Cohort 1 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="B2">
          <title>CPP-115 Dose 2</title>
          <description>Cohort 2a consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="B3">
          <title>CPP-115 Dose 2 (Repeat)</title>
          <description>Cohort 2(b) consisted of 7 subjects with 5 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="B4">
          <title>CPP-115 Dose 3</title>
          <description>Cohort 3 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="B5">
          <title>CPP-115 Dose 4</title>
          <description>Cohort 4 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="B6">
          <title>CPP-115 Dose 5</title>
          <description>Cohort 5 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Progression to the next higher dose level was contingent upon demonstration of a satisfactory assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="B7">
          <title>CPP-115 Dose 6</title>
          <description>Cohort 1 consisted of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects receiving matching placebo solution. Assessment of safety based on committee review the safety data obtained from this dose.&#xD;
Placebo : 5 ml water mixed with ~250 ml juice was administered.&#xD;
CPP-115 : Appropriate amount of drug substance dissolved in 5 ml water will be dissolved in ~250 ml juice within 3 hours of dosing.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="13.01"/>
                    <measurement group_id="B2" value="32.6" spread="5.67"/>
                    <measurement group_id="B3" value="35.2" spread="12.11"/>
                    <measurement group_id="B4" value="38.8" spread="4.83"/>
                    <measurement group_id="B5" value="40.8" spread="9.93"/>
                    <measurement group_id="B6" value="38.0" spread="10.6"/>
                    <measurement group_id="B7" value="35.5" spread="7.5"/>
                    <measurement group_id="B8" value="36.8" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of Single Oral Doses</title>
        <description>Number of subjects with clinically significant changes in vital signs, ECG abnormalities changes of cardiac rhythm, serious or severe AEs, and/or clinically significant changes in clinical laboratory evaluations.</description>
        <time_frame>Days 1-3, 8 &amp; 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CPP-115 Dose 1 (5mg)</title>
            <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
          </group>
          <group group_id="O2">
            <title>CPP-115 Dose 2 (13mg)</title>
            <description>2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
          </group>
          <group group_id="O3">
            <title>CPP-115 Dose 3 (32mg)</title>
            <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
There were no deaths or SAEs&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered.</description>
          </group>
          <group group_id="O4">
            <title>CPP-115 Dose 4 (80mg)</title>
            <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
          </group>
          <group group_id="O5">
            <title>CPP-115 Dose 5 (200mg)</title>
            <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
          </group>
          <group group_id="O6">
            <title>CPP-115 Dose 6 (500mg)</title>
            <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Single Oral Doses</title>
          <description>Number of subjects with clinically significant changes in vital signs, ECG abnormalities changes of cardiac rhythm, serious or severe AEs, and/or clinically significant changes in clinical laboratory evaluations.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Descriptive statistics for evaluation of AEs</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Comparison of event rates across dose groups.</non_inferiority_desc>
            <param_type>percentage</param_type>
            <param_value>14.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>There were a total of 5 non-serious adverse events for an AE rate of 14.3%</estimate_desc>
            <other_analysis_desc>Descriptive statistics of adverse events</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Solicited and all events were considered treatment related. There were no SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>CPP-115 Dose 1</title>
          <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
        </group>
        <group group_id="E2">
          <title>CPP-115 Dose 2</title>
          <description>2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
        </group>
        <group group_id="E3">
          <title>CPP-115 Dose 3</title>
          <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
There were no deaths or SAEs&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered.</description>
        </group>
        <group group_id="E4">
          <title>CPP-115 Dose 4</title>
          <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
        </group>
        <group group_id="E5">
          <title>CPP-115 Dose 5</title>
          <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
        </group>
        <group group_id="E6">
          <title>CPP-115 Dose 6</title>
          <description>Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.&#xD;
CPP-115: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.&#xD;
Placebo: An equal volume of water mixed with juice will be administered. There were no deaths or SAEs</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood CPK increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Groin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Douglas Winship, Vice President of Regulatory Operations</name_or_title>
      <organization>Catalyst Pharmaceutical Partners, Inc.</organization>
      <phone>305 529-2522 ext 12</phone>
      <email>dwinship@catalystpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

